Plasma homocysteine and folate are related to arterial blood pressure in type 2 diabetes mellitus

American Journal of Hypertension

Volumn 11, Issue 9, 1998, Pages 1100-1107

  Fiorina, Paolo ^a   Lanfredini, Mario ^b   Montanari, Alberto ^b   Peca, Maria Grazia ^b   Veronelli, Annamaria ^b   Mello, Alessandra ^b   Astorri, Ettore ^b   Craveri, Angelo ^b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b NONE

Author keywords

Albumin excretion; Arterial blood pressure; Folate; Homocysteine; Non insulin dependent diabetes

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; FEMALE; FOLIC ACID BLOOD LEVEL; HOMOCYSTINURIA; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MEAN ARTERIAL PRESSURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; URINARY EXCRETION;

AGED; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; DIABETES MELLITUS, TYPE 2; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED;

EID: 0032169606     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(98)00125-3     Document Type: Article

References (36)

1. 1. Sebastio G, Sperandeo MP, Panico M, et al: The molecular basis of homocystinuria due to cystathionine β-synthase deficiency in Italian families and report of four novel mutations. Am J Hum Genet 1995;56:1324-1333.
2. 2. Mudd S, Levy H, Skoby F: Disorders of transsulfuration, in Scriver C, Beaudet A, Sly W, Valle D (eds): The Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill, New York, 1995, pp 1279-1327.
3. 3. Kang S, Wong P: Genetic and nongenetic factors for moderate hyperhomocysteinemia. Atherosclerosis 1996; 119:135-138.
4. 4. Bostom A, Shemin D, Lapane KL, et al: Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control study. Atherosclerosis 1995;114:93-103.
5. 5. Tsai JC, Wang H, Perrella MA, et al: Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. J Clin Invest 1996;97:146-153.
6. 6. Lentz SR, Sobey CG, Piegors DJ, et al: Vascular dysfunction in monkeys with diet induced hyperhomocysteinemia. J Clin Invest 1996;98:24-29.
7. 7. Rodgers GM, Conn MT: Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 1990;75:895-901.
8. 8. Lentz SR, Sadler JE: Homocysteine inhibits von Willebrand factor processing and secretion by preventing transport from the endoplasmic reticulum. Blood 1993; 81:683-689.
9. 9. Blom HJ, Kleinveld HA, Boers GHJ, et al: Lipid peroxidation and susceptibility of low-density lipoprotein to in vitro oxidation in hyperhomocysteinaemia. Eur I Clin Invest 1995;25:149-154.
10. 10. Harman LS, Mottley C, Mason RP: Free radical metabolites of L-cysteine oxidation. J Biol Chem 1984;259: 5606-5611.
11. 11. Van Den Berg M, Boers GHJ, Franken DG, et al: Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest 1995;25:176-181.
12. 12. Stamler JS, Osborne JA, Jaraki O, et al: Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993;91:308-318.
13. 13. Lentz SR, Sadler JE: Inhibition of thrombomodulin surface expression and protein C activation by thrombogenic agent homocysteine. J Clin Invest 1991;88:1906-1914.
14. 14. Morrison HI, Schaubel D, Desmeules M, Wigle DT: Serum folate and risk of fatal coronary artery disease. JAMA 1996;275:1893-1896.
15. 15. Malinow MR, Levenson J, Giral P, et al: Role of blood pressure, uric acid and hemorheological parameters on plasma homocyst(e)ine concentration. Atherosclerosis 1995;114:175-183.
16. 16. Levenson J, Malinow MR, Giral PH, et al: Increased plasma homocyst(e)ine levels in human hypertension (abst). J Hypertens 1994;12:S74.
17. 17. Araki A, Sako Y, Fukushima Y, et al: Plasma sulfhydryl-containing amino acids in patients with cerebral infarction and in hypertensive subjects. Atherosclerosis 1989;79:139-143.
18. 18. Pedrinelli R, Giampietro O, Carmassi E, et al: Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994;334:14-18.
19. 19. World Health Organization: WHO Study Group on Diabetes Mellitus. Geneva, World Health Organization, 1985. Technical report series 727.
20. 20. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure: The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1993;153:154-183.
21. 21. Bostom AG, Jacques PF, Nadeau MR, et al: Post-methionine load hyperhomocysteinemia in persons with normal fasting total plasma homocysteine: initial results from The NHLBI Family Heart Study. Atherosclerosis 1995;116:147-151.
22. 22. Ubbink JB, Hayward Vermaak WJ, Bissbort S: Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatography 1991;565:441-446.
23. 23. Selhub J, Jacques PF, Wilson PWF, et al: Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693-2698.
24. 24. Rees MM, Rodgers GM. Homocysteinemia: association of a metabolic disorder with vascular disease and thrombosis. Thrombosis Res 1993;71:337-339.
25. 25. Malinow MR, Kang SS, Taylor LM, et al: Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation 1989;79:1180-1188.
26. 26. Malinow MR, Ducimetiere P, Luc G, et al: Plasma homocyst(e)ine levels and graded risk for myocardial infarction: findings in two populations at contrasting risk for coronary artery disease. Atherosclerosis 1996;126: 27-34.
27. 27. Wilcken DEL, Wilcken B: The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest 1976;57:1079-1082.
28. 28. Malinow MB: Hyperhomocyst(e)inemia. A common and easily reversible risk factor for occlusive atherosclerosis. Circulation 1990;81:2004-2006.
29. 29. Coull BM, Malinow MR, Beamer N, et al: Elevated plasma homocyst(e)ine in acute stroke and TIA: a possible independent risk factor for stroke. Stroke 1990;21: 572-576.
30. 30. Robillon JF, Canivet B, Candito M, et al: Type 1 diabetes mellitus and homocyst(e)ine. Diabete Metabol 1994; 20:494-496.
31. 31. Hultberg B, Agardh E, Anderson A, et al: Increased levels of plasma homocyst(e)ine are associated with nephropathy, but not with severe retinopathy in type 1 diabetes mellitus. Scan J Clin Invest 1991;51:277-282.
32. 32. Genest JJ, McNamara JR, Salem DN, et al: Plasma homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol 1990;16:1114-1119.
33. 33. Araki A, Sako Y, Ito H: Plasma homocysteine concentrations in Japanese patients with non-insulin-dependent diabetes mellitus: effects of parenteral methylcobalamin treatment. Atherosclerosis 1993;103:149-157.
34. 34. MacMahon S, Peto R, Cutler J, et al: Blood pressure, stroke, and coronary artery disease: Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-774.
35. 35. Williams SB, Cusco JA, Roddy MA, et al: Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. JACC 1996; 27:567-574.
36. 36. Sutton-Tyrrell K, Bostom A, Selhub J, Zeigler-Johnson C: High homocysteine levels are indepently related to isolated systolic hypertension in older adults. Circulation 1997;96:1745-1749.